Management of Persistent Hypertension in Young ESRD Patients on Dialysis

Blood Pressure Targets

• Aim for a systolic blood pressure of 120–129 mmHg in young patients with end‑stage renal disease to provide cardiovascular protection and potential cognitive benefit (European Society of Cardiology). 3
• Older target of <130/80 mmHg is no longer recommended; recent evidence supports lower targets when measured correctly (KDIGO). 1
• Control hyperthyroidism before intensifying antihypertensive therapy, as thyrotoxicosis can raise blood pressure (KDIGO). 4

Dialysis‑Based Volume Management (Primary Strategy)

• Optimize volume status before adding medications; volume overload is the main driver of hypertension in dialysis patients (KDIGO). 4
• Extend dialysis treatment duration to allow gentler ultrafiltration rather than aggressive fluid removal in standard 4‑hour sessions (Praxis). 2
• Target ultrafiltration rates < 10–13 mL/kg/h to minimize intradialytic hypotension while achieving euvolemia (Praxis). 2
• Gradually lower dry‑weight targets to attain true euvolemia (KDIGO). 4
• Consider increasing dialysis frequency (e.g., home or nocturnal schedules) if volume control remains inadequate with thrice‑weekly sessions (Praxis). 2
• Restrict dietary sodium to < 2 g/day to reduce interdialytic weight gain and facilitate blood pressure control (Praxis). 2

Pharmacologic Therapy

Continuation of Losartan

• Continue losartan (an ARB) for its cardioprotective effects beyond blood pressure reduction, especially in patients with diabetic nephropathy (KDIGO). 5

Second‑Line Antihypertensive Agent

• Add a calcium‑channel blocker (CCB) as the preferred second agent in dialysis patients because it provides consistent blood pressure reduction without reliance on volume status (American Academy of Family Physicians). 6
• Beta‑blockers (e.g., carvedilol, metoprolol succinate, bisoprolol) are reasonable alternatives for patients with concurrent heart failure or coronary disease (Praxis). 2
• Avoid thiazide diuretics in patients with eGFR ≈ 5 mL/min/1.73 m², as they are ineffective at this level of kidney function (American Academy of Family Physicians). 6
• Do not combine losartan with an ACE inhibitor or a direct renin inhibitor because dual RAS blockade increases risks of hyperkalaemia, hypotension, and acute kidney injury without added benefit (KDIGO). 5

Initiation and Dosing Strategy

• If blood pressure remains >20/10 mmHg above goal after volume optimization, start a two‑drug combination rather than sequential monotherapy titration (American Academy of Family Physicians). 6
• Use the highest approved tolerated doses of each agent, as trial benefits were demonstrated at these doses (KDIGO). 5

Anemia Management

• CKD‑related anemia contributes to hypertension via increased cardiac output and sympathetic activation (KDIGO). 8
• Assess iron status with serum ferritin and transferrin saturation (TSAT), recognizing limitations in dialysis patients (KDIGO). 8
• Define absolute iron deficiency as TSAT < 20 % and ferritin < 200 µg/L (KDIGO). 8
• Prefer intravenous iron over oral iron for hemodialysis patients because of superior efficacy and bioavailability (KDIGO). 8
• Monitor for ESA‑induced hypertension; 35–44 % of dialysis patients experience blood pressure rises during ESA therapy, especially with rapid hematocrit correction (KDIGO). 4

Thyroid Management

• Achieve adequate control of hyperthyroidism, as thyrotoxicosis independently elevates blood pressure through increased cardiac output, heart rate, and systemic vascular resistance (European Society of Cardiology). 3

Monitoring Strategy

• Use standardized office blood pressure measurement with automated oscillometric devices following proper technique (KDIGO). 1
• Add home blood pressure monitoring to capture interdialytic patterns and avoid white‑coat effects (KDIGO). 1
• Re‑check blood pressure, serum creatinine, and serum potassium 2–4 weeks after starting or adjusting losartan or adding a second agent (KDIGO). 5
• Monitor hemoglobin, ferritin, and TSAT regularly during anemia management (KDIGO). 8

Critical Pitfalls to Avoid

• Do not intensify antihypertensive drugs before optimizing dialysis adequacy and volume status, as volume overload is the primary cause of hypertension in dialysis patients (KDIGO). 4
• Avoid aggressive ultrafiltration to rapidly lower blood pressure, which can cause hemodynamic instability and intradialytic hypotension (Praxis). 2
• Never combine losartan with ACE inhibitors or aliskiren, due to increased harm without benefit (KDIGO). 5
• Do not overlook hyperthyroidism as a contributor to hypertension; thyroid control is essential for successful blood pressure management (KDIGO). 4